ArticleMediterranean journal of rheumatology2026
Evaluation of the Safety of Recombinant Zoster Vaccine on Patients with Systemic Lupus Erythematosus in a Tertiary Hospital in Saudi Arabia: A Retrospective Single Centre Study.
Article in Mediterranean journal of rheumatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Herpes Zoster (HZ) infection is more severe in patients with Systemic lupus erythematosus (SLE). Recent guidelines recommend the Recombinant Zoster Vaccine (RZV) for prevention of HZ in immunocompromised adults aged ≥18 years. RZV has demonstrated efficacy against HZ infection in immunocompromised populations, but data regarding its safety among SLE patients are lacking, especially those who are on biological therapy. Objective: Evaluation of the safety of RZV among SLE patients, including patients on biological therapy. Method: A retrospective study of 170 patients with SLE who received at least one dose of RZV and 45 unvaccinated SLE patients were included. Data were extracted from the King Fahad Medical City (KFMC) hospital database system. Data analysis was carried out using Statistical methods. Results: A study involved 170 SLE patients who received RZV (90.6% females, with a mean age of 38.5 years and an SLE duration of 8.5±6.2 years). Seventy percent completed two doses of RZV. The mean baseline, post-first-dose, and post-second-dose SLEDAI scores were 3.43±5.27, 3.31±3.11, and 2.97±2.78, respectively, indicating no significant change. A subset of patients was treated with biological therapies, including Belimumab, Rituximab, and Anifrolumab. The incidence of SLE flare within 90 days was 12.9% after the first dose and 12.3% after the second dose. There was a statistically significant association between higher baseline SLEDAI scores and flares after both doses. Conclusion: Vaccination with RZV in patients with SLE is safe and not associated with increased SLE activity which is comparable with unvaccinated patients. The reported side effects were mild and comparable to those of the general population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.